Evidence – Using Translational Models to Overcome Tumour Antigen Heterogeneity & Improve CAR-T Responses in Solid Tumours
8:30 am - Wednesday 2nd December 2026
- Understanding how tumour antigen heterogeneity contributes to resistance and variable patient responses in CAR-T therapy
- Leveraging translational model systems to evaluate strategies that overcome antigen escape and improve therapeutic durability
- Applying insights from the CARKey platform to develop more consistent and clinically meaningful responses across diverse patient populations
